BLPH

Bellerophon Therapeutics Inc.

Price

return (12m)

p/e

0.00

p/bv

0.00

DIVIDEND YIELD

0.00%

BLPH price

Bellerophon Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*The amount considers the reinvestment of dividends.

Return on Investment BLPH

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals BLPH

Valuation

P/E

0.00

Sector 0.84

Industry -1.42

P/BV

0.00

Sector 1.82

Industry 1.25

P/Revenue (PSR)

Sector 1.48

Industry 2.13

EV/EBITDA

Sector -43.66

Industry -35.45

EV/EBIT

Sector -47.57

Industry -38.86

P/EBITDA

Sector -31.25

Industry -21.12

P/EBIT

Sector -42.58

Industry -25.59

P/Total Assets

Sector 0.82

Industry 0.70

P/Net Current Assets

Sector -23.77

Industry -59.56

P/Working Capital

Sector -3.73

Industry -1.93

EPS

0.07

Sector -0.70

Industry -1.22

BVPS

0.30

Sector 4.50

Industry 2.78

Efficiency

Gross Margin

0.00%

Sector 49.32%

Industry 49.70%

EBITDA Margin

Sector -305.63%

Industry -17,123,193.33%

EBIT Margin

0.00%

Sector -19.73%

Industry -25.36%

Net Profit Margins

0.00%

Sector -23.90%

Industry -27.40%

Asset Turnover

0.00

Sector 0.13

Industry 0.06

Profitability

ROE

22.35%

Sector -24.30%

Industry -38.97%

ROA

16.71%

Sector -24.50%

Industry -49.14%

ROIC

Sector -584.46%

Industry -1,072.15%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

Sector 1.92

Industry 2.55

Net Debt / EBITDA

Sector -23.10

Industry -8.80

Net Debt / EBIT

Sector -17.84

Industry -36.75

Net Debt / Equity

Sector -0.68

Industry -1.16

Gross Debt / Equity

Sector -0.72

Industry -0.54

Equity/Assets

0.75

Sector 0.46

Industry 0.52

Liabilities/Assets

0.25

Sector 0.50

Industry 0.47

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals BLPH

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Bellerophon Therapeutics ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$0.00

Fair Value

$0.69

Upside

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
BLPH Bellerophon Therapeutics Inc.	$0.00	-	0.00%	0.00	0.00	22.35%	0.00%
ABT Abbott Laboratories	$103.75	-16.91%	2.53%	31.55	3.35	10.61%	11.65%
MDT Medtronic PLC	$92.84	0.14%	3.02%	23.20	2.39	10.29%	13.93%
BSX Boston Scientific Corp.	$44.56	-55.10%	0.00%	17.83	2.63	14.73%	17.49%
TMDX TransMedics Group Inc.	$72.35	-38.50%	0.00%	16.36	4.79	29.28%	22.69%
RMD ResMed Inc.	$239.43	-9.75%	1.03%	22.76	5.27	23.13%	26.94%
IDXX IDEXX Laboratories Inc.	$556.87	-12.36%	0.00%	38.87	27.47	70.67%	25.03%
COHR Coherent Inc.	$240.39	106.61%	0.00%	57.23	4.10	7.16%	11.31%
SYK Stryker Corp.	$298.82	-19.12%	1.18%	30.25	4.70	15.55%	14.43%
PHG Koninklijke Philips NV	$25.60	-6.71%	3.91%	19.13	1.87	9.80%	6.30%
INMD InMode Ltd.	$14.09	-7.97%	0.00%	10.83	1.33	12.32%	20.69%
BDX Becton Dickinson and Company	$190.65	3.33%	2.20%	55.79	2.15	3.85%	6.29%
DXCM DexCom Inc.	$85.63	28.57%	0.00%	33.25	12.68	38.14%	20.12%
EW Edwards Lifesciences Corp.	$86.82	16.32%	0.00%	49.74	4.66	9.37%	15.43%
ALGN Align Technology Inc.	$147.89	13.37%	0.00%	25.13	2.46	9.77%	9.99%
SNN Smith & Nephew PLC	$28.84	-17.84%	2.68%	21.68	4.71	21.74%	9.20%
IRMD iRadimed Corporation	$88.03	21.26%	1.43%	49.39	11.19	22.66%	26.70%
ZBH Zimmer Biomet Holdings Inc.	$94.68	-5.87%	1.02%	22.50	1.44	6.39%	9.48%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

BLPH - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Bellerophon Therapeutics

Bellerophon Therapeutics Inc.

Average Investor10 user rating

4.0 (1 people)

United States

13 years

Founded: 2013

2015

Time since IPO - 11 years

21

Employees

Bellerophon Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $-, with shareholders equity totaling $3.72 million.

The company employs approximately 21 people and operates in the Health sector, within the Medical Supplies and Equipment industry.

Over the past 12 months, Bellerophon Therapeutics Inc. reported $- in revenue, generating net income of $831.98 Thousand.

Key financial metrics include a P/E ratio of 0.00, a price-to-book (P/B) ratio of 0.00, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker BLPH.

Market cap

Net worth

$3.72 million

$3,723,000.00

Assets

$4.98 million

$4,979,000.00

Total Shares Outstanding

12.23 million

12,232,000

Average Daily Trading Volume

Sector

Health

Industry

Medical Supplies and Equipment

BLPH

BLPH revenue and profits

Financial Results BLPH

DRAG THE FRAME TO SEE MORE DATA

BLPH cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

CVS - CVS Health

$91.15 14,82% (12M)

P/E

24.09

2.89%

ROE

6.12%

P/BV

1.47

CI - Cigna

$296.71 1,38% (12M)

P/E

11.63

2.05%

ROE

16.04%

P/BV

1.87

CNC - Centene

$68.16 93,24% (12M)

P/E

-6.73

0.00%

ROE

-22.53%

P/BV

1.52

HUM - Humana

$411.55 52,12% (12M)

P/E

39.10

0.85%

ROE

6.63%

P/BV

2.59

SNY - Sanofi

$39.81 --18,25% (12M)

P/E

3.78

4.38%

ROE

18.43%

P/BV

0.70

JNJ - Johnson & Johnson

$252.71 34,46% (12M)

P/E

29.04

2.08%

ROE

24.76%

P/BV

7.19

LLY - Eli Lilly

$1,249.76 56,65% (12M)

P/E

42.13

0.53%

ROE

78.84%

P/BV

33.21

HCA - HCA Healthcare

$454.64 7,19% (12M)

P/E

14.90

0.66%

ROE

-213.15%

P/BV

-31.76